In quest of one of the most powerful, yet elusive biomarkers of our time – tumour-derived Circulating Endothelial Cells (tCEC) – X-ZELL has developed a four-part platform technology allowing researchers to analyse tissue and blood samples at a whole new level of detail and empowering them to pose the kind of research questions they’ve never been able to ask before.
Perfected in a real life laboratory environment as part of our daily workflow, all four platform devices continue to prove themselves on the international research circuit as part of our ongoing investigation into the potential of tCEC as novel biomarkers for clinically significant, early-stage cancers.
From 26 March 2019, we will make two of the system’s four core elements available to researchers worldwide – the X-ZELL Cryoimmunostaining™ Suite as well as the corresponding microscopy toolkit.
Proprietary Cell Lysis
hMX™ Magnetic Cell Separation
Comprised of two high-performance devices, the X-ZELL CryoFixator™ and the X-ZELL CryoStainer™, X-ZELL’s patented Cryoimmunostaining™ Suite allows researchers to apply up to nine biomarkers at a time to cells fixated on standard laboratory slides – making it one of the most powerful cytology tools in the world today. Available for Research Use Only.
Automated Microscopic Analysis
X-ZELL has refined semi-automated widefield fluorescence microscopy to identify and analyze cancer cells on a standard laboratory slide – allowing for classic cancer pathology to be applied to circulating tumour-derived cells at the single cell level. Well-described hallmarks of cancer can be re-discovered in isolated cancer cells and cell clumps, including aneuploidy, polyploidy, the expression of stem cell markers, mesenchymal makers, epithelial markers, cell proliferation markers, apoptotic markers and more, enabling diagnostics based on solid visual evidence.